CARDIOGENI PLC

Active Stratford-Upon-Avon
0 employees website.com
Life sciences and medical technology
C

CARDIOGENI PLC

Founded 28 Dec 2016 Active Stratford-Upon-Avon, England 0 employees website.com
Life sciences and medical technology

Previous Company Names

CARDIOGENI LIMITED 6 Jan 2025 — 6 Jan 2025
CELIXIR LIMITED 17 Feb 2021 — 6 Jan 2025
CELIXIR PLC 28 Dec 2016 — 17 Feb 2021
Accounts Submitted 11 Nov 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 22 May 2026 Next due 21 May 2027 11 months remaining
Net assets £833K £7M 2024 year on year
Total assets £1M £301K 2024 year on year
Total Liabilities £631K £8M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Celixir House Stratford-Upon-Avon Business & Technology Park Innovation Way Stratford-Upon-Avon CV37 7GZ England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for CARDIOGENI PLC (10541091), an active life sciences and medical technology company based in Stratford-Upon-Avon, England. Incorporated 28 Dec 2016. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type group
Next accounts 31 Mar 2026
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2017–2024)

Cash in Bank

£85.00k

Decreased by £248.17k (-74%)

Net Assets

£833.00k

Increased by £7.34M (+113%)

Total Liabilities

£631.00k

Decreased by £7.64M (-92%)

Turnover

£7.85M

Increased by £7.18M (+1077%)

Employees

N/A

Decreased by 4 (-100%)

Debt Ratio

43%

Decreased by 426 (-91%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2024
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4

Investors (4)

Investor NameInvestor SinceParticipating Rounds
Investor 2May 2022Debt Financing
Investor 3May 2022Debt Financing
Investor 1Feb 2025Strategic Investment

Share Capital

Share Capital

Share allotments and capital structure

18 Allotments 910,159,427 Shares £1941.21m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
1 Feb 20265,785,670£58k£58k
31 Jan 20252,341,869£23k£0.01
31 Jan 20252,341,869£23k£0.01
12 Dec 20241,360,527£14k£0.01
12 Dec 202474,704,194£747k£0.01

Officers

Officers

3 active
Status
Disley, Darrin Matthew, Dr.DirectorBritishEngland5812 Apr 2017Active
Evans, Martin John, SirDirectorBritishWales8526 Jan 2018Active
Hurvitz, ChaimDirectorIsraeliIsrael6512 Apr 2017Active

Shareholders

Shareholders (1)

Sanaclis C.r.o
0.2%

Persons with Significant Control

Persons with Significant Control (0)

0 Active 1 Ceased

Ajan Trevor Reginald

Ceased 12 Apr 2017

Ceased

Group Structure

Group Structure

CARDIOGENI PLC Current Company
CELL THERAPY LIMITED united kingdom
DESKTOP GENETICS LTD united kingdom
CELIXIR LIMITED united kingdom
SIRNA LIMITED united kingdom

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
22 May 2026OfficersTermination of Joanne Elizabeth Martin as director on 31 Jan 2025
22 May 2026Confirmation StatementConfirmation statement made on 7 May 2026 with no updates
21 May 2026OfficersAppointment of Professor Joanne Elizabeth Martin as director on 31 Jan 2025
17 Mar 2026CapitalAllotment of shares (GBP 948,894.29) on 16 Mar 2026
11 Nov 2025AccountsAnnual accounts made up to 31 Mar 2025
22 May 2026 Officers

Termination of Joanne Elizabeth Martin as director on 31 Jan 2025

22 May 2026 Confirmation Statement

Confirmation statement made on 7 May 2026 with no updates

21 May 2026 Officers

Appointment of Professor Joanne Elizabeth Martin as director on 31 Jan 2025

17 Mar 2026 Capital

Allotment of shares (GBP 948,894.29) on 16 Mar 2026

11 Nov 2025 Accounts

Annual accounts made up to 31 Mar 2025

Recent Activity

Latest Activity

Termination of Joanne Elizabeth Martin as director on 31 Jan 2025

2 weeks ago on 22 May 2026

Confirmation statement made on 7 May 2026 with no updates

2 weeks ago on 22 May 2026

Appointment of Professor Joanne Elizabeth Martin as director on 31 Jan 2025

2 weeks ago on 21 May 2026

Allotment of shares (GBP 948,894.29) on 16 Mar 2026

2 months ago on 17 Mar 2026

Annual accounts made up to 31 Mar 2025

6 months ago on 11 Nov 2025